Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
Factors to Consider When Thinking About Switching a Patient's ARV Regimen
Factors to Consider When Thinking About Switching a Patient's ARV Regimen
Managing ART for Optimal Cardiometabolic Health
Managing ART for Optimal Cardiometabolic Health
Cardiometabolic Disease in Patients with HIV: Who's at Greatest Risk?
Cardiometabolic Disease in Patients with HIV: Who's at Greatest Risk?
Patients at High Risk for Poor Cardiometabolic Outcomes: Is Switching Regimens an Option?
Patients at High Risk for Poor Cardiometabolic Outcomes: Is Switching Regimens an Option?
ART and Cardiometabolic Health: What's the Connection?
ART and Cardiometabolic Health: What's the Connection?
My Patient Is Stable on ART, But Has Gained 30 Pounds: What Are My Options?
My Patient Is Stable on ART, But Has Gained 30 Pounds: What Are My Options?
Weight Creep: The Overlooked Vital Sign in Patients with HIV
Weight Creep: The Overlooked Vital Sign in Patients with HIV
HIV and Cardiometabolic Health: What's the Connection?
HIV and Cardiometabolic Health: What's the Connection?
Defense: Argument for Single Agent ICI Adjuvant Treatment of Stage III Melanoma
Defense: Argument for Single Agent ICI Adjuvant Treatment of Stage III Melanoma
Expert Panel: What Is the Future of Early Intensification in Localized Prostate Cancer?
Expert Panel: What Is the Future of Early Intensification in Localized Prostate Cancer?
Closing Arguments in the Case of Anti-CTLA-4-based Versus Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma
Closing Arguments in the Case of Anti-CTLA-4-based Versus Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma
What Is the Future of Neoadjuvant ARI Intensification in Localized Prostate Cancer?
What Is the Future of Neoadjuvant ARI Intensification in Localized Prostate Cancer?
Prosecution: Argument for Anti-CTLA-4-based Frontline Combination ICI Treatment of Stage IV Melanoma
Prosecution: Argument for Anti-CTLA-4-based Frontline Combination ICI Treatment of Stage IV Melanoma